secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapid Therapeutic Science Laboratories, Inc. (—)
CIK:        0001575659
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0001393905-23-000314
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RTSL extends $2.35M convertible debt to Dec 2023, issues 5M warrants at $0.01
-----------------------------------------------------------------------------

- Amended two convertible debentures totaling $2,352,940; maturity extended to earliest of qualified offering, exchange listing, or Dec 31, 2023.
- Conversion price set at 65% of lowest 10-day VWAP; existing warrants repriced to $0.01/share, extended to Aug 2028.
- Issued new warrants for 5,000,000 shares at $0.01 with 5.5-year term expiring Feb 2029; full mutual release of all past claims.
- Company had been in continuous default since Sep 2022; all prior defaults waived under the agreement.
- Potential dilution includes 582,354 shares from existing warrants plus 5M from new warrants, all at $0.01.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1575659/000139390523000314/0001393905-23-000314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1575659/000139390523000314/rtsl-20230822.htm
  HTML page:      https://secwatch.observer/filing/0001393905-23-000314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer